SecProbe.io

<DOCUMENT>
<TYPE>LETTER
<SEQUENCE>1
<FILENAME>ctic1-0l.txt
<DESCRIPTION>ACCTG CMNTS DATED 10/29/04 - ITEM 4 8-K FILED 10/19/04 - YOUNG
<TEXT>

Via Facsimile and U.S. Mail
Mail Stop 03-09

October 29, 2004

Mr. Louis A. Bianco
Executive Vice President, Finance and Administration
Cell Therapeutics, Inc.
501 Elliott Avenue West, Suite 400
Seattle, WA  98119

Re:	Cell Therapeutics, Inc.
Form 8-K filed October 19, 2004
File No. 000-12465

Dear Mr. Bianco:

We have reviewed your filing and have the following comments.  Where
indicated, we think you should revise your document in response to
these comments.  If you disagree, we will consider your explanation
as to why our comment is inapplicable or a revision is unnecessary.
Please be as detailed as necessary in your explanation.  In some of
our comments, we may ask you to provide us with supplemental
information so we may better understand your disclosure.  After
reviewing this information, we may or may not raise additional
comments.

	Please understand that the purpose of our review process is to
assist you in your compliance with the applicable disclosure
requirements and to enhance the overall disclosure in your filing.
We look forward to working with you in these respects.  We welcome
any questions you may have about our comments or on any other aspect
of our review.  Feel free to call us at the telephone numbers listed
at the end of this letter.

1. We urge all persons who are responsible for the accuracy and
adequacy of the disclosure in the filings reviewed by the staff to be
certain that they have provided all information investors require.
Since the company and its management are in possession of all facts
relating to a company`s disclosure, they are responsible for the
accuracy and adequacy of the disclosures they have made.

In connection with responding to our comments, please provide, in
writing, a statement from the company acknowledging that

* the company is responsible for the adequacy and accuracy of the
disclosure in the filing;

* staff comments or changes to disclosure in response to staff
comments in the filings reviewed by the staff do not foreclose the
Commission from taking any action with respect to the filing; and

* the company may not assert staff comments as a defense in any
proceeding initiated by the Commission or any person under the
federal securities laws of the United States.

In addition, please be advised that the Division of Enforcement has
access to all information you provide to the staff of the Division of
Corporation Finance in our review of your filing or in response to
our comments on your filing.

2. To better comply with Item 304(a)(2) of Regulation S-K, please
disclose whether you consulted with the new accountant during the two
most recent fiscal years and the subsequent interim period through
the date the new accountant was engaged, as "prior to such date" does
not appear to be sufficiently clear.

3. Please consider revising the Commission File Number that you
disclose (000-28386).  We did not note any filings to that Commission
File Number subsequent to 1996.  Instead, it appears that this and
other filings have been submitted to a different Commission File
Number (001-12645).

Please file your supplemental response and amendment via EDGAR in
response to these comments within 5 business days of the date of this
letter.  Please note that if you require longer than 5 business days
to respond, you should contact the staff immediately to request
additional time.  Direct any questions regarding the above to me at
(202) 942-2902.

							Sincerely,

							Oscar M. Young, Jr.
							Staff Accountant
Mr. Louis A. Bianco
Cell Therapeutics, Inc.
Page 1

</TEXT>
</DOCUMENT>